Non-pharmaceutical Motion Sickness Mitigation

Healthy Clinical Trial

Official title:

Non-pharmaceutical Motion Sickness Mitigation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04859868
• Other study ID #: 20-005763
• Secondary ID: 80NSSC21K0175
• Status: Completed
• Phase: N/A
• Start date: March 12, 2021
• Est. completion date: August 30, 2022

Study information

• Verified date: September 2023
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is evaluate the effect of timing and magnitude on the administration of our nonpharmaceutical treatment to motion sickness, and to evaluate the effect of Galvanic Vestibular Stimulation (GVR) amplitude on functional fitness task performance.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 29
• Est. completion date: August 30, 2022
• Est. primary completion date: August 30, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 21 Years to 55 Years

Eligibility

Inclusion Criteria:

• Must be able to consent to participate themselves.

• Must be able to attend in-person sessions at the Mayo Aerospace Medicine and Vestibular Research Laboratory in Scottsdale, AZ.

• No racial ethnic groups will be excluded.

• Must be fluent speakers of English.

Exclusion Criteria:

• History of vestibular disease, migraine, or significant balance disorder.

• Traumatic brain injury.

• Recent middle ear infection or recent motion sickness (within 72 hours).

• History of severe motion sensitivity.

• Women who are pregnant.

Related Conditions & MeSH terms

• Healthy
• Motion Sickness

Intervention

Device:
• Galvanic Vestibular Stimulation
Low electrical currents to the vestibular system, to induce the realistic sensation of motion (i.e., the g-forces that occur during flight) as well as null out motion perception.

Locations

Country	Name	City	State
United States	Mayo Clinic in Arizona	Scottsdale	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Motion Perception	Motion Perception verbal report using a visual analog scale (1-100) will be recorded during the rotation of the chair (1=feeling no motion perception; 100=feeling the maximum motion perception)	During the rotation of the chair, approximately 1 hr
Secondary	Motion Sickness Questionnaire	subjective experiences of motion sickness in a scale of 0-10 (0=not at all; 10=most severe)	During the rotation of the chair, approximately 1 hr

External Links

•   Mayo Clinic Clinical Trials